Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 vs 4 Doses of Recombinant Hep B Vaccine in Hemodialysis Patients
NCT07784452Completed
- Sponsor
- Jinnah Hospital
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of recombinant hepatitis B vaccine Bio Farma in hepatitis B (HBV) (2 arms), sponsored by Jinnah Hospital. Primary endpoint: Proportion of Participants Achieving Seroprotection (Anti-HBs Titer ≥10 mIU/mL) at 7 months. Started Dec 2025; status: completed.
02
Drugs
recombinant hepatitis B vaccine Bio Farma
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07784452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784452.